Amyloid Beta Therapeutics Market Revenue to Attain USD 26.50 Bn by 2035

Amyloid Beta Therapeutics Market Revenue and Trends 2026 to 2035

The global amyloid beta therapeutics market revenue surpassed USD 5.20 billion in 2025 and is predicted to attain around USD 26.50 billion by 2035, growing at a CAGR of 17.80%. The market is gaining pace as Alzheimer’s cases climb worldwide, diagnoses are shifting earlier, and newly approved therapies have turned a once-speculative research field into a commercially active treatment segment.

Market at a Glance

The amyloid beta therapeutics market refers to the segment of the pharmaceutical industry focused on treatments designed to target, reduce, block, or remove amyloid-beta proteins linked to Alzheimer’s disease pathology. It includes monoclonal antibodies, vaccines, enzyme inhibitors, and supportive drug candidates aimed at slowing cognitive decline, especially in early-stage patients. The market also covers related diagnostics, infusion services, and monitoring systems that support treatment delivery and long-term disease management.

The scope of the amyloid beta therapeutics industry stretches beyond drug sales into diagnostics, biomarker screening, infusion care, imaging support, and follow-up monitoring. It spans early Alzheimer’s intervention, hospital and specialty clinic use, pipeline innovation, and geographic expansion as healthcare systems prepare for broader adoption of disease-modifying therapies.

Market Forecast for the Amyloid Beta Therapeutics Market

• Earlier Diagnosis is Driving the Market : The FDA notes Alzheimer’s affects more than 6.5 million Americans. As blood-based biomarker tests and PET confirmation become more common, more patients may enter treatment while still in mild stages, the sweet spot for amyloid beta therapeutics.
• Rising Demand for Home-Based Autoinjector Therapy: One of the biggest hurdles in this market has been infusion-center dependence. Eisai and Biogen stated that LEQEMBI IQLIK, if approved for starting-dose use, would allow patients to begin therapy at home through a subcutaneous autoinjector. That could widen access in rural regions, reduce hospital burden, and improve patient continuity.

FDA Approval Expands Amyloid Beta Treatment Market

• In July 2024, the U.S. FDA approved Kisunla (donanemab-azbt), giving the amyloid beta therapeutics market a second major commercial growth pillar after earlier approvals. 
• Alzheimer’s currently affects more than 6.5 million Americans, sustaining a large treatment-eligible population for plaque-targeting drugs. 
• Kisunla’s pivotal study enrolled 1,736 patients, reflecting strong late-stage clinical investment in amyloid beta assets. 
• Patients were treated across 277 sites in 8 countries, signaling broad multinational demand and commercialization readiness. 
• The trial showed a 2.92-point benefit on iADRS versus placebo at Week 76, strengthening physician confidence in disease-modifying therapy uptake. 
• With multiple approved antibodies now competing, the amyloid beta market has shifted from theory-driven science to revenue-bearing neurology business.

Market Segmentation Overview

• By therapeutic type, the monoclonal antibodies segment accounted for a considerable revenue share of 48.0% in the market in 2025, because approvals of anti-amyloid biologics gathered pace, and growing demand for disease-modifying Alzheimer’s therapies. Strong clinical attention toward amyloid plaque reduction, paired with deeper investment in biologics development, helped this segment command commercial confidence and sustained demand.
• By therapeutic type, the combination therapies segment is expected to grow at the fastest CAGR of 21.5% in the amyloid beta therapeutics market between 2026 and 2035, as drug developers increasingly pursue multi-target strategies for neurodegeneration. The growing interest in pairing amyloid and tau mechanisms, alongside demand for stronger therapeutic outcomes, is likely to accelerate pipeline activity.
• By indication, the Alzheimer’s disease segment dominated the market with a 62.0% market share in 2025 and is expected to maintain its leading position with a CAGR of 18.5% in the coming years, due to the high prevalence of Alzheimer’s disease globally. Demand for disease-modifying therapies increased as clinical focus sharpened around amyloid beta reduction, while strong clinical focus on amyloid beta pathology reduction and larger neurology research budgets continued to strengthen treatment development.
• By mechanism of action, the amyloid plaque clearance segment dominated the market with a 40.0% market share in 2025 and is expected to maintain its leading position with a CAGR of 20.0% in the coming years, because antibody-mediated therapies removing plaque gained the earliest traction and strongest visibility. Expanding clinical evidence supporting amyloid clearance, together with regulatory approvals of biologics targeting amyloid plaques, helped this mechanism secure the broadest commercial foothold.
• By route of administration, the intravenous (IV) segment held a major revenue share of 56.0% in the amyloid beta therapeutics market in 2025, due to the penetration of monoclonal antibody therapies. Hospitals and specialty clinics already had the infrastructure to enable supervised dosing, and they emphasized treatment environments that focused on biologics for safety monitoring and treatment efficacy assessment.
• By route of administration, the subcutaneous segment is steadily growing with a CAGR of 20.0% in the market between 2026 and 2035, due to an increasing number of companies developing self-administered biologic treatments for outpatient use. Patients are likely to favor this route of administration due to its ease of use, fewer required clinic visits, and more convenient long-term therapy options that enhance overall patient experience.
• By end-use, the hospitals segment accounted for a considerable revenue share of 42.0% in the market in 2025, as they handled the majority of infusion-based amyloid therapies and specialist neurology consultations. Strong patient inflow for neurodegenerative care, combined with access to advanced departments and monitoring resources, kept hospitals at the center of treatment delivery.
• By end-use, the pharmaceutical and biotechnology companies segment is expected to expand rapidly in the market with a CAGR of 24.0% in the coming years, due to rising investment in Alzheimer’s drug development pipelines. Expanding clinical development of amyloid-targeted therapeutics, licensing deals, and strategic partnerships focused on amyloid-targeted assets are likely to intensify innovation and market momentum.

Regional Analysis

North America dominated the global amyloid beta therapeutics market with a market share of 46.0% in 2025, due to strong FDA approvals and an active clinical development pipeline that accelerated the commercialization of novel antibodies. The region also carried a high Alzheimer’s burden across its aging population, encouraging faster treatment uptake. Large investments in neurodegenerative therapeutics and the presence of leading biotechnology and pharmaceutical companies reinforced market depth. In the United States, regulatory momentum remained strongest, while Canada advanced through research funding, specialist memory clinics, and growing patient access pathways.

Asia-Pacific held a market share of 18.0% in 2025 and is expected to grow at the fastest CAGR of 22.0% in the market during the forecast period, as China and Japan face rapidly aging populations that are enlarging the Alzheimer’s patient pool. Governments are increasing healthcare expenditure on neurological diseases, while regional clinical trial activity continues to broaden. Rising biotechnology investment is also nurturing local innovation and partnerships. Japan is expected to lead through early adoption and mature healthcare systems, whereas China is likely to expand through scale, infrastructure, and domestic biotech development.

Amyloid Beta Therapeutics Market Coverage

Top Companies in the Amyloid Beta Therapeutics Market

Biogen Inc. and Eisai Co., Ltd. are among the first widely recognized disease-modifying therapies to gain major regulatory traction in Alzheimer’s care. F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., and Johnson & Johnson remained important strategic names due to their neuroscience capabilities, biologics expertise, capital strength, and ability to enter or expand through licensing, partnerships, and adjacent neurodegenerative research programs. AC Immune SA, Alzheon Inc., Cassava Sciences, TauRx Pharmaceuticals, Prothena Corporation, Cognition Therapeutics, and Annovis Bio represented the innovation tier of the market.

Segments Covered in the Report

By Therapeutic Type

• Monoclonal Antibodies
  
  • Anti-amyloid Beta Antibodies
  • Passive Immunotherapies
• Small Molecule Therapies
  
  • Beta-secretase (BACE) Inhibitors
  • Gamma-secretase Inhibitors
• Vaccines
  
  • Active Immunotherapies
  • Peptide Vaccines
• Combination Therapies
  
  • Amyloid & Tau Combination Therapies
  • Multi-target Neuroprotective Therapies

By Indication

• Alzheimer's Disease
• Mild Cognitive Impairment (MCI)
• Early-stage Alzheimer's
• Other Neurodegenerative Disorders

By Mechanism of Action

• Amyloid Plaque Clearance
• Amyloid Production Inhibition
• Neuroinflammation Reduction
• Synaptic Protection
• Neuroprotection Enhancement

By Route of Administration

• Intravenous (IV)
• Oral
• Subcutaneous

By End-use

• Hospitals
• Specialty Neurology Clinics
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8428

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344